Results 221 to 230 of about 242,578 (253)

Interleukin-6 receptor inhibitor suppresses bone metastases in a breast cancer cell line

Breast Cancer, 2018
Interleukin-6 (IL-6) is a potent inflammatory cytokine that appears to play a key role in cancer growth and metastasis. In the present study, the effects of IL-6 receptor (IL-6R) on breast cancer aggressiveness and bone metastases were investigated.MDA-MB-231 (MDA-231) cells were treated in the presence or absence of anti-human IL-6 receptor (IL-6R ...
Hiroki, Wakabayashi, Takahiko, Hamaguchi, Nobuto, Nagao, Sho, Kato, Takahiro, Iino, Tomoki, Nakamura, Akihiro, Sudo   +6 more
openaire   +2 more sources

In vivo effects of the anti–interleukin‐6 receptor inhibitor tocilizumab on the B cell compartment

Arthritis & Rheumatism, 2011
AbstractObjectiveInterleukin‐6 (IL‐6) receptor inhibition by tocilizumab was recently licensed for the treatment of rheumatoid arthritis (RA). IL‐6 induces in vitro differentiation of B cells into antibody‐forming cells; however, the in vivo effects of IL‐6 inhibition on the B cell compartment are currently not known.
Petra, Roll, Khalid, Muhammad, Mathias, Schumann, Stefan, Kleinert, Hermann, Einsele, Thomas, Dörner, Hans-Peter, Tony   +6 more
openaire   +2 more sources

Tocilizumab: The first interleukin-6-receptor inhibitor

American Journal of Health-System Pharmacy, 2008
The pharmacology, pharmacokinetics, clinical efficacy, safety, and role of tocilizumab in rheumatoid arthritis (RA) are reviewed.Tocilizumab is a novel monoclonal antibody that competitively inhibits the binding of interleukin-6 (IL-6) to its receptor (IL-6R).
openaire   +2 more sources

Significance of Interleukin-6 Signaling in the Resistance of Pharyngeal Cancer to Irradiation and the Epidermal Growth Factor Receptor Inhibitor

International Journal of Radiation Oncology*Biology*Physics, 2010
Tumor eradication by chemoradiotherapy for pharyngeal cancer has not been particularly successful. Targeting epithelial growth factor receptor (EGFR) could be a potential treatment strategy providing additional benefits, but only a subset of these tumors gives a clinically significant response to EGFR inhibitors.
Chih-Cheng, Chen, Wen-Cheng, Chen, Chang-Hsien, Lu, Wen-Hung, Wang, Paul-Yang, Lin, Kuan-Der, Lee, Miao-Fen, Chen   +6 more
openaire   +2 more sources

Interleukin-6 Receptor Inhibitor Therapy Is Associated with Improved Outcomes in Patients with Severe COVID-19 Disease

SSRN Electronic Journal, 2020
Background: The impact of interleukin-6 receptor inhibitors (IL6ri) on Coronavirus disease 2019 (Covid-19) outcomes remains uncertain. Methods: Patients with severe and critical Covid-19 were given an IL6ri (sarilumab or tocilizumab) based on pragmatic and iteratively reviewed guidelines at a safety net hospital with a diverse population.
Pranay Sinha, Anahita Mostaghim, Catherine G. Bielick, Angela McLaughlin, Davidson H. Hamer, Lee M. Wetzler, Nahid Bhadelia, Maura A. Fagan, Benjamin P. Linas, Sabrina A Assoumou, Michael H. Ieong, Nina H Lin, Ellen R. Cooper, Karrine D. Brade, Laura F. White, Tamar F. Barlam, Manish Sagar   +16 more
openaire   +1 more source

Effect of interleukin-6 receptor inhibitor, tocilizumab, in preventing joint destruction in patients with rheumatoid arthritis showing inadequate response to TNF inhibitors

Modern Rheumatology, 2013
To examine the effectiveness of tocilizumab (TCZ) in preventing joint destruction in patients with inadequate response to tumor necrosis factor inhibitors (TNF-IR) by assessing X-rays.RA patients were extracted from the Retrospective actemra investigation for optimal needs of RA patients (REACTION) study.
Yoshiya, Tanaka, Tsutomu, Takeuchi, Koichi, Amano, Kazuyoshi, Saito, Kentaro, Hanami, Masao, Nawata, Shunsuke, Fukuyo, Hideto, Kameda, Yuko, Kaneko, Takahiko, Kurasawa, Hayato, Nagasawa, Daisuke, Hoshi, Eri, Sato, Hisashi, Yamanaka   +13 more
openaire   +2 more sources

Interleukin 6 receptor inhibitor tocilizumab suppresses cytokine expression, inflammasome activation and phagocytosis in a cell model of sepsis

Die Pharmazie, 2016
Objective: Sepsis is a life-threatening condition, usually accompanied by excessive inflammation. Tocilizumab (TCZ) is a humanized monoclonal antibody against the interleukin (IL) 6 receptor and has been studied in various inflammatory diseases, but little is known about its effects in sepsis.
Fen Sheng, Fen Sheng, Minghui Han, Minghui Han, Zongxuan Huang, Zongxuan Huang, Lingling Zhang, Lingling Zhang   +3 more
openaire   +2 more sources

Tocilizumab: An lnterleukin-6 Receptor Inhibitor for the Treatment of Rheumatoid Arthritis

Annals of Pharmacotherapy, 2008
Objective: To review the pharmacology, pharmacokinetics, clinical trial data, and safety profile of tocilizumab, a new biologic agent targeting the lnterleukin-6 cytokine receptor. Data Sources: A systematic search of MEDLINE (1998 ...
openaire   +2 more sources

Establishment of a New Interleukin-6 (IL-6) Receptor Inhibitor Applicable to the Gene Therapy for IL-6–Dependent Tumor

Cancer Research, 2007
Abstract Interleukin-6 (IL-6) is a key molecule involved in the pathogenesis of several inflammatory diseases and malignancies. Treatments that inhibit IL-6 mitigate the clinical conditions of such diseases. Here, we report on the development of a new receptor inhibitor of IL-6 (NRI) by genetically engineering tocilizumab, a humanized ...
Naoko, Yoshio-Hoshino, Yasuo, Adachi, Chieko, Aoki, Alexander, Pereboev, David T, Curiel, Norihiro, Nishimoto   +5 more
openaire   +2 more sources

Interleukin-6 receptor inhibitor levilimab in the treatment of COVID-19 in patients with chronic kidney disease

Nephrology, 2023
Kim I.G. Kim, Frolov M.A. Frolov, Terentyeva N.V. Terentyeva, Sysoeva I.L. Sysoeva, Dyakova E.N. Dyakova, Usatyuk S.S. Usatyuk, Tomilina N.A. Tomilina, Frolova N.F. Frolova   +7 more
openaire   +1 more source